Response to Comments: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This document is a response-to-comments notice for MolDX Local Coverage Determination L39927 concerning non-next-generation sequencing tests for diagnosing BCR-ABL-negative myeloproliferative neoplasms. The comment period ran from 08/01/2024 to 09/15/2024; the notice period for L39927 begins 07/03/2025 and the LCD will become effective 08/17/2025. This document contains comments received from the provider community and does not itself state clinical coverage criteria.